Please assess the completion status of the following clinical trial:

Trial Title: Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Presented to Regions Hospital ED for chief complaint of DKA, nausea, vomiting, abdominal pain, hyperglycemia, or similar~2. Meets all below diagnostic criteria for DKA per the American Diabetes Association:~   * Arterial or venous pH \</= 7.3~  * Serum Bicarbonate \</= 18 mEq/L~  * Ketonuria or ketonemia~  * Anion Gap \> 10~  * Blood sugar \> 250 mg/dL~3. Receiving IV insulin infusion~4. It is feasible to provide insulin glargine within 2 hours (+/- 30 minutes) of IV infusion start~5. Will be admitted to the ICU for DKA, or already admitted to the ICU for DKA~6. Ability to provide informed consent~Exclusion Criteria:~1. Age \< 18~2. End stage renal disease or hepatic disease~3. Hypotension requiring IV vasopressors or inotropes at any point during admission (i.e. norepinephrine, dobutamine, vasopressin, etc.)~4. Need for emergent surgery~5. Pregnant patients~6. Prisoners~7. Indication for insulin therapy other than DKA (hypertriglyceridemia, beta-blocker overdose, hyperglycemia without DKA)~8. Patients receiving prior to admission insulin pump therapy~9. Patients receiving prior to admission combination insulin products (i.e. Novolin® 70/30, Novolog® 70/30, Humalog® 75/25, etc.)~10. Did not consent to study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Subjects presenting to ED with diagnosis of DKA and receiving intravenous short acting insulin will not have orders for subcutaneous insulin glargine placed for research purposes.
- Intervention (Type: ACTIVE_COMPARATOR): Subjects presenting to ED with diagnosis of DKA will receive study medication set to begin within 2 hours after initiation of the IV insulin infusion. The dose will come from IV pharmacy and dispensed in a 1 mL insulin syringe. If the patient was not taking basal insulin prior to admission, the patient will receive 0.2 units/kg insulin glargine. If the patient was taking basal insulin prior to admission, the patient will receive their home insulin glargine dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).